Top Biotech and Pharma Stocks to Bet on Cancer Cure & Control

The technicals do not look good at all – with a decline lasting over the past two months. He would not touch this one at all. A 50 day moving average would be a buy signal if it can trade back above it.

Likes turnarounds, but it’s not ready. Want to see two things: 1) the stock hitting a 52-week high, and 2) the numbers moving in the right direction. Don’t do anything until then. Odds are this is going to zero.

Brazilian order? He owns warrants and his wife works as a consultant for them. They have orders for 500 units for a melanoma testing product. The delivery is subject to approval by authorities in Brazil. This could lead to hardware sales by June and revenues that begin to show up in Q4. The company thinks…

This name has been beaten up and now offers value. There is concern that markets could experience a pull-back and one way to play that is this one. It is a large entity in the healthcare space and has under-performed its space. As we push out of the pandemic we are going to see increased…

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

Stockchase Research Editor: Michael O'Reilly We reiterate BMY, a $139 billion marketcap pharma player, as a TOP PICK. The recent $13 billion acquisition of a company that focuses on blood cancer treatment has gone well, but analysts have held the stock value back as the drug will lose patent protection in 2023. If you believe…

One of the world's largest biopharma companies. Expected revenue of 97B USD this year. Likes it because of its rapidly improving pipeline, especially the cardio drug. Vaccine will produce cashflow windfalls over the near term, plus lots of runway. Continuing shots needed, anti-viral pill will be in high demand. Good valuation. Yield is 2.86%, expected…

An advisor could help the caller decide whether to hold or sell some. He doesn't own either The devices made by Abbott show promise for the stock so there is upside. The pharmaceutical side is not of particular interest. These are relatively defensive stocks but market could gravitate to cyclicals.

(A Top Pick Jan 10/20, Up 25%) A great buy here. Model price of $214.71, 25% upside. Yield is 2.44%.

(A Top Pick Nov 06/20, Down 1%) They just announced huge inflows after they redeemed their stake in Roche. They continue to do (and will do) more tuck-in acquisitions. And yet, it's a stock that can't get any love. There's no big news in the pipeline. Strong balance sheet. Tuck-ins will continue and it's possible…

Options trading He jumped on some options. He likes healthcare and is adding to the sector. he doing call buying with Glaxo, not stock buying. There's a lot of activity here.

(A Top Pick Apr 06/21, Up 13.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AZN has triggered its stop at $56. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 21% when combined with the previous recommendation to cover half the position.

(A Top Pick Oct 27/20, Up 16.7%)Stockchase Research Editor: Michael O'Reilly Our PREVIOUS TOP PICK with GILD is progressing well. To remain disciplined, we recommend trailing up the stop (from $50) to $64 at this time.

On Monday, they host an investors' event to showcase their work in RNA-based therapies and gene editing. Though it's a biotech, REGN is profitable and trades at a low PE. It trades on earnings and not future sales. If they tell a great story next week, he expects this stock to break out to an…

A great spec. It's a genetic engineering company so it's bought on spec, not earnings.

(A Top Pick Aug 29/14. Up 2.34%.) Radiation therapy equipment for treating cancer. Have been affected a little by foreign exchange rates. These are big ticket purchases, so she expects purchases have been delayed, but she has seen this come back. On the emerging-market side, it is a little bit more challenging. Still thinks the…

(A Top Pick Jan 10/20, Down 3%) Stock price popped on news of therapeutic pill. We're in a medical emergency, yet drug space is languishing, quite extraordinary. Lots of value. Model price of $146, 90% upside. Yield is 3.4%

As the Fed is about to raise interest rates, buy companies that make real, concrete things. This includes pharmas. Since he started buying this in October, it's rallied. It's up 58% YTD. Last week, it held an investor day and soared 10% in one day, but then pulled back. Why he likes it? Their drug…

Has owned this many years. It's sensitive to the Covid testing environment, like now during Omicron. So, it's has a nice run from this increasing demand. But the market always looks forward, so Abbott doesn't enjoy that testing rise. They report later this month. She is waiting for a slightly lower entry point. Nobody knows…